Skip directly to content

Inflectra™ (infliximab)

What is Inflectra and what is it used for?

Inflectra’s active substance is called infliximab which is a type of protein of human and mouse origin.

Inflectra belongs to a group of medicines called “TNF blockers” and it is used in adults for the following inflammatory diseases:

  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis (Bechterew’s disease)
  • Psoriasis

Inflectra is also used in adults and children 6 years of age and older for:

  • Crohn’s disease
  • Ulcerative colitis

Inflectra works by blocking the action of a protein called “tumour necrosis factor alpha” (TNFα).  This protein is involved in the inflammatory processes of the body and blocking it can reduce inflammation in the body.

Inflectra is a Prescription Only Medicine and is given by a doctor or nurse in a hospital or clinic as an infusion over a few hours.


Reference Information
  • If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for Inflectra these can be found at the electronic Medicines Compendium (eMC).
  • The European Medicines Agency (EMA) is an agency of the European Union (EU), responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on Inflectra.


Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

PP-IFA-GBR-0444 / Sept 2020